跳至主要内容
临床试验/ISRCTN60069084
ISRCTN60069084进行中(未招募)3 期

Inflammatory regulation effect of N-acetylcysteine on COVID-19 treatment, pilot, double blinded randomized placebo controlled multicenter clinical trial

King Saud Medical City0 个研究点目标入组 1,180 人开始时间: 2020年7月19日最近更新:

试验速览

阶段
3 期
状态
进行中(未招募)
入组人数
1,180

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Adults (above 18 years)
  • 2. Admitted to the hospital
  • 3. Confirmed COVID-19 patient by RT-PCR test from any specimen (nasal, throat swab, sputum, etc)
  • 4. On oxygen supplement ( Category 4, 5, 6, 7 on the ordinal scale)

排除标准

  • 1. Active indication and use of NAC
  • 2. Known allergy to NAC
  • 3. In the opinion of the clinical team, progression to death is imminent and inevitable within the next 24 hours, irrespective of provision of treatment e.g. patients on ECMO at time of randomization
  • 4. Patients enrolled in other investigational drug studies are not eligible for our study

研究者

相似试验